Synaptogenix, Inc. (NASDAQ:SNPX) Sees Significant Growth in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPX) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 14,400 shares, an increase of 100.0% from the June 30th total of 7,200 shares. Based on an average daily volume of 43,900 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.2% of the company’s shares are sold short.

Synaptogenix Price Performance

Synaptogenix stock traded up $0.11 during trading on Friday, reaching $4.25. The company had a trading volume of 41,744 shares, compared to its average volume of 43,668. Synaptogenix has a 12-month low of $3.53 and a 12-month high of $20.25. The stock’s 50 day moving average price is $4.35 and its two-hundred day moving average price is $4.73.

Synaptogenix (NASDAQ:SNPX) last released its earnings results on Wednesday, May 15th. The company reported ($0.41) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded shares of Synaptogenix from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Thursday, July 11th.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.